Infectivity of blood products from donors with occult hepatitis B virus infection. - Test2 - elhamkhani - TriplyDB

Infectivity of blood products from donors with occult hepatitis B virus infection.

Infectivity of blood products from donors with occult hepatitis B virus infection.

http://www.wikidata.org/entity/Q42277057

about

Asymptomatic Hepadnaviral Persistence and Its Consequences in the Woodchuck Model of Occult Hepatitis B Virus Infection Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine Occult hepatitis B viral infection among blood donors in South-Eastern Nigeria Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors.Occult hepatitis B virus infection and blood transfusion Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases.Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq.Virus and Host Testing to Manage Chronic Hepatitis B.Medical virology of hepatitis B: how it began and where we are now Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy.A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections.Molecular and serological detection of occult hepatitis B virus among healthy hepatitis B surface antigen-negative blood donors in Malaysia.Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.Transfusion transmitted infections in thalassaemics: need for reappraisal of blood screening strategy in India.Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Occult hepatitis B virus infection in Egypt.Screening and diagnosis of HBV in low-income and middle-income countries.Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections.Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing.Refining the risk estimate for transfusion-transmission of occult hepatitis B virus.Use of supplemental anti-HBc testing of donors showing non-discriminating reactive results in multiplex nucleic acid testing.A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios.Rare transmission of hepatitis B virus by Dutch donors with occult infection.Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China.Hepatitis B virus infection in blood donors in Argentina: prevalence of infection, genotype distribution and frequency of occult HBV infection.Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.Evaluation of an individual-donation nucleic acid amplification testing algorithm for detecting hepatitis B virus infection in Chinese blood donors.Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply.Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme.Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.What is the meaning of a nonresolved viral nucleic acid test-reactive minipool?Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.Stochastic model for estimating the risk of transfusion-transmitted hepatitis B in Vietnam.Occult hepatitis B infections among blood donors in Lao PDR.

P2860

Q26775638-942346AB-52DC-49D4-9399-0BDF3B3A2A66 Q26799246-ABFCDF09-2CF6-4814-A0C0-1F83E9FBACE8 Q28542694-952CA62E-FEEC-4E19-871C-79E6A5E61D94 Q34129673-CAEDFFF9-500A-4354-A58A-0D68CFD5732F Q35164580-F1D192A7-069B-4436-862D-E8078EE9C467 Q35237335-27B1D7CC-4F93-437B-95E6-C0FBE3339645 Q35274812-DE0E5A34-B1C3-4850-B774-76B32F937930 Q36662183-DD1867FC-04FE-44DA-802D-334AE26EFA13 Q36958940-31AC6319-82F4-4DE2-A7D6-D266340E2ACB Q37059714-4C4874ED-6187-4F2D-8EBD-59D771B84DA5 Q37305696-3CF5B939-6BFE-4EEA-8465-15BDDE5C77AA Q37305718-8748457F-BD1D-43C4-B5C6-BB11246446E9 Q37418340-A658F4E8-497F-4F57-9FD6-F9FC5E073B48 Q37618604-B8458452-EB0E-4424-9A50-33BA46CF044E Q38194183-117B3BB5-C58B-45DD-A9E8-ABB45820B02F Q38223372-82F2D336-EE38-4803-BFF7-F4E4CEEEB0FB Q38293584-EF26A062-0C41-4784-9688-F6DE7954043B Q38536404-67BEA24B-4339-4BFE-82C6-F27F54A75934 Q38542377-F6A65284-3BA3-4C56-9A0D-E83D175673D8 Q38953790-93EF63F5-AB88-4C98-8B9E-CF005685BB79 Q39131395-3EFB013C-6288-4BFD-8049-6DE56963E856 Q39347172-9F453175-34E9-4397-88A0-AD88A9284991 Q39450759-C38B00E0-9E02-46F4-B94A-3BBD4A02D350 Q40048372-F4C3BC19-CF84-486C-8AE9-8F5E879212F2 Q40314561-EA6298BF-BC94-45E5-A032-F37EAF3A6ECB Q40331727-381817B6-92C6-496F-A735-936E16F7DB60 Q40613598-7333AA3C-70D5-4B82-9649-D9B6A36E408C Q40623803-D36A595D-5D3E-4C4D-B48D-DB446E671002 Q40818421-6BEDC9EE-C4AB-45D7-8298-AC19442E3244 Q41107028-0F2FA6D4-4994-4D45-8193-0086B7A431ED Q41111337-80676FD3-BDE1-421C-9C6D-EDCA2E465164 Q41606333-B0D35B18-7DDE-4AEB-8E56-046547915B2D Q41680549-B62C39E9-2DCC-4DBD-8796-DA480F343AA1 Q41734031-019F0E7C-13AD-417B-9ED0-FC08EA269E8C Q42173073-ECC38B5E-05C1-451D-A779-133ED88CA674 Q42199830-B2EFB618-20CA-4E9D-BB3B-526841AF15AF Q42230165-C9881FC0-9F44-46B2-A05F-20DE5979412F Q42257442-06836B9B-F6D3-45CC-86DC-BC0D7BA3F4F1 Q42258103-C50417BF-1F90-4299-A47D-F8258E985F8C Q42277833-F69BEC58-6124-4FBB-B5C9-55F4C5A411A9

P2860

Infectivity of blood products from donors with occult hepatitis B virus infection.

http://www.wikidata.org/entity/Q42277057

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Infectivity of blood products from donors with occult hepatitis B virus infection.

@en

Infectivity of blood products from donors with occult hepatitis B virus infection.

@nl

type

label

Infectivity of blood products from donors with occult hepatitis B virus infection.

@en

Infectivity of blood products from donors with occult hepatitis B virus infection.

@nl

prefLabel

Infectivity of blood products from donors with occult hepatitis B virus infection.

@en

Infectivity of blood products from donors with occult hepatitis B virus infection.

@nl

P1433

Q42277057-3640F565-9548-47E2-B4D9-EF84CC365B37

P1476

Q42277057-B5D12F0E-C78A-4A45-8030-A4A63CB0B917

P2093

Q42277057-0B2CACC7-3C00-4010-B915-DA57D9B5E162

Q42277057-11C28E4E-ECD7-462C-8D56-5A2EC0D3DAEB

Q42277057-2686BE74-9C0C-4028-A794-4223C7618953

Q42277057-336F2609-6FB5-4B0A-B9DB-6D2B5AC9F241

Q42277057-4748C5B2-BF6C-4F02-B787-C6B9EAB1F153

Q42277057-5E374BBC-9C2B-40D3-82A4-F8AA85252A2D

Q42277057-62027C16-EDAA-4416-BF95-27BA3041B678

Q42277057-78291299-0B48-49D0-B49C-F39A894642F0

Q42277057-80F102C4-8709-4CFF-9E4A-17E6990676D7

Q42277057-8E561003-F688-4E10-BDC4-1545659924E3

P2860

Q42277057-0631E4B6-437A-4098-8934-51D5EEDAF47A

Q42277057-15C2AA39-0506-468A-B339-2A5CF613280E

Q42277057-177B7018-5059-4290-8470-C5B56D278233

Q42277057-41292326-C5B1-47BF-BA2F-8D3F2C555257

Q42277057-426B449D-F328-48E1-9D74-2906F30AB6FE

Q42277057-4F4E2E29-1C1C-4497-91AE-6FA73B435DD9

Q42277057-5DAD2C9C-884D-4869-8781-E3F0C94C3A43

Q42277057-61BA6AC6-3E69-4A20-82C8-C683D34C6BC0

Q42277057-6BAE9BE6-C6F6-47CA-9A09-3451D592D62F

Q42277057-834B381E-E22A-4BB4-93BA-01E0E8B9C311

P304

Q42277057-08FCAF4E-E57B-477C-B951-EF9D484B6655

P31

Q42277057-080EE5D9-E200-499A-A691-E9F8C5C0BB00

P356

Q42277057-EE93FA7D-9CC3-4DC7-B6F2-166BAE522DED

P433

Q42277057-C840623E-51F9-4B18-B7D8-A3C85B994C83

P478

Q42277057-C3B59AD7-F139-4261-8F5F-40A0F0CF3A1C

P50

Q42277057-56186F02-2628-414F-A073-E9D591BE0FF0

Q42277057-B66BE72C-27B5-4AE0-8313-4D811567C3CE

P577

Q42277057-DCEF9A0E-1767-4044-BF7A-A7A914DFF59A

P5875

Q42277057-F05CA87F-1A5B-4E71-85AF-EC199971869C

P698

Q42277057-82688AB3-4F28-4C2D-9CFB-4464A17AE71C

P356

P1433

P1476

Infectivity of blood products from donors with occult hepatitis B virus infection.

@en

P2093

Christian Erikstrup

http://www.w3.org/2001/XMLSchema#string

Daniel Candotti

http://www.w3.org/2001/XMLSchema#string

Ivanka Mihaljevic

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Allain

http://www.w3.org/2001/XMLSchema#string

Jose Maria Garcia

http://www.w3.org/2001/XMLSchema#string

Knut Gubbe

http://www.w3.org/2001/XMLSchema#string

Lene Holm-Harritshøj

http://www.w3.org/2001/XMLSchema#string

Lorenz Wernish

http://www.w3.org/2001/XMLSchema#string

Lydia Bianco

http://www.w3.org/2001/XMLSchema#string

Maria Isabel Gonzalez-Fraile

http://www.w3.org/2001/XMLSchema#string

P2860

Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.

Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.

HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus.

Challenges in hepatitis B detection among blood donors.

Infectivity of pre-seroconversion donations: an analysis of lookback exercises in The Netherlands, 2000-2006.

The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study.

Hepatitis B virus genotype G monoinfection and its transmission by blood components.

Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection.

Occult hepatitis B virus in liver tissue of individuals without hepatic disease.

Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection.

P304

1405-1415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.12096

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235384050

http://www.w3.org/2001/XMLSchema#string

P698

23362802

http://www.w3.org/2001/XMLSchema#string